High-dose therapy in acute leukemia

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Intensive induction chemotherapy, including anthracycline and cytarabine combinations, yields >70% complete remission rates in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
• Current standard-dose therapies result in only 20% cure rates for young adults with these leukemias.
• Effective post-remission strategies are essential to significantly increase cure rates.

Purpose of the Study:

• To evaluate the efficacy of different post-remission therapeutic options for AML and ALL.
• To determine the optimal strategy for increasing cure rates in young adults with leukemia.
• To assess the role of stem cell transplantation in improving leukemia-free survival.

Main Methods:

• Review of randomized trials comparing dose-intensified chemotherapy, allogeneic stem cell transplantation, and autologous stem cell transplantation.
• Evaluation of prognostic factors including cytogenetic, molecular, and phenotypic characteristics.
• Analysis of outcomes based on different therapeutic interventions.

Main Results:

• Randomized trials confirm improved leukemia-free survival with both allogeneic and autologous stem cell transplantation.
• Autologous stem cell transplantation demonstrates significant promise as a treatment modality for AML.
• Further investigation is needed to define the optimal methods and role of stem cell transplantation in adult ALL.

Conclusions:

• Post-remission therapy, particularly stem cell transplantation, is critical for improving cure rates in AML and ALL.
• Autologous stem cell transplantation is a highly promising approach for AML, with preparative regimens and purging techniques being key factors.
• The optimal application of stem cell transplantation in adult ALL requires further research.